$AMBS Company Profile Inside!!

Amarantus BioScience is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.

Neurodegenerative diseases such as Parkinson’s, ALS and Alzheimer’s as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s Disease and other human diseases.

Amarantus owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.  Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI.  The Company also has a diagnostic program led by NuroPro® which is aimed at developing diagnostic blood tests that are capable of early identification of apoptosis-related medical conditions while tracking their progression over time.

Amarantus BioScience intends to advance its therapies and diagnostics to provide patients with safe and effective treatment options in the care of their chronic illnesses.